Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat.

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol. 2014 Oct; 43(10):1353-60.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.